Multiresponse optimization of the properties of albendazole-chitosan microparticles

Journal of Pharmaceutical and Biomedical Analysis

Volumn 48, Issue 3, 2008, Pages 802-807

  Leonardi, Dario ^a,b   Lamas, Maria C ^a,b   Olivieri, Alejandro C ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Albendazole; Chitosan; Dissolution; Microparticles; Optimization; Response surface

Indexed keywords

ALBENDAZOLE; CHITOSAN;

ARTICLE; DRUG FORMULATION; DRUG SOLUBILITY; IONIZATION; PH; PRIORITY JOURNAL;

ALBENDAZOLE; ANTHELMINTICS; BIOCOMPATIBLE MATERIALS; CHITOSAN; CROSS-LINKING REAGENTS; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; SODIUM HYDROXIDE; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; TEMPERATURE;

EID: 53049104146     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.08.006     Document Type: Article

References (14)

1. United States Pharmacopeia XXVI, USP Convention, 12601 Twinbrook Parkway, Rockville, MD, 2003, pp. 53-55.
2. Zongde Z., Xingping L., Xiaomei W., Hong Z., Yanping S., Liren C., and Yong Ming L.J. Biochem. Biophys. Methods 62 (2005) 69-79
3. Polat C., Dervisoglu A., Hokelek M., Yetim I., Buyukkarabacak Y., Ozkutuk Y., and Erzurumlu K.J. J. Gastroenterol. Hepatol. 20 (2005) 421-425
4. Wong S.M., Kellaway I.W., and Murdan S. Int. J. Pharm. 317 (2006) 61-68
5. Torrado S., Torrado S., Torrado J.J., and Cadorniga R. Int. J. Pharm. 140 (1996) 247-250
6. Diaz D., Bernad Bernad M.J., Gracia Mora J., and Escobar Llanos C.M. Pharm. Dev. Technol. 3 (1998) 395-403
7. Dressman J.B., Reppas C., and Testa B. Eur. J. Pharm. Sci. Suppl. 2 (2000) S73-S80
8. Tu J., Bolla S., Barr J., Miedema J., Li X., and Jasti B. Int. J. Pharm. 303 (2005) 171-181
9. Chandy T., and Sharma C.P. J. Biomater. Appl. 13 (1998) 128-157
10. Krauland A.H., Guggi D., and Bernkop Schnürch A. Int. J. Pharm. 307 (2006) 270-277
11. Jain S.K., Rai G., Saraf D.K., and Agrawal G.P. Pharm. Technol. (2004) 66-71
12. Rai G., Jain S.K., Agrawal S., Bhadra S., Pancholi S.S., and Agrawal G.P. Pharmazie 60 (2005) 131-134
13. FDA guidance of industry, ICH Q8 pharmaceutical development, U.S. Department of Health and Human Services, FDA/CDER/CBER, 2006.
14. Myers R.H., and Montgomery D. Response Surface Methodology (1995), John Willey & Sons Inc., New York